4//SEC Filing
Farag Kameel D. 4
Accession 0001493152-25-028419
CIK 0001541157other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 9:57 PM ET
Size
9.2 KB
Accession
0001493152-25-028419
Insider Transaction Report
Form 4
Farag Kameel D.
Interim CFO
Transactions
- Purchase
Warrants to purchase American Depositary Shares ("ADRs")
2025-12-16+24,745→ 24,745 totalExercise: $0.39→ American Depositary Shares representing Ordinary Shares (24,745 underlying) - Purchase
Pre-Funded Warrants to purchase ADRs
2025-12-16$0.40/sh+24,745$9,999→ 24,745 totalExercise: $0.00→ American Depositary Shares representing Ordinary Shares (24,745 underlying)
Footnotes (5)
- [F1]Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.
- [F2]On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 24,745 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 24,745 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.
- [F3]The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised.
- [F4]The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.
- [F5]Conversion Exercise Price of Security is $0.00001
Documents
Issuer
Akari Therapeutics Plc
CIK 0001541157
Entity typeother
Related Parties
1- filerCIK 0002093620
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 9:57 PM ET
- Size
- 9.2 KB